Neumora Therapeutics(NMRA) - 2026 Q3 - Quarterly Results

Exhibit 99.1 Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration Dose-proportional increase in exposure observed in multiple ascending dose (MAD) expansion cohort with NMRA- 511 (V1aR antagonist), suggesting potential to build on the efficacy profile demonstrated in Phase 1b study WATERTOWN, Mass., November 16, 2026 – Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinic ...

Neumora Therapeutics(NMRA) - 2026 Q3 - Quarterly Results - Reportify